# Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06993844/  
OnCo record `nct06993844` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Ensem Therapeutics, now recruiting.

## Summary

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06993844 by Ensem Therapeutics, with 233 participants planned, started 2025-06-10 and due to reach its primary completion in 2027-06-30. Interventions recorded: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant and ETX-636 dose expansion in combination with fulvestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06993844
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors
- Sponsor: Ensem Therapeutics
- Enrolled: 233

## Sources

- ClinicalTrials.gov NCT06993844: https://clinicaltrials.gov/study/NCT06993844

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/)

---
JSON: https://onco.cc/api/v1/entities/nct06993844.json